A DHEA-S blood test measures dehydroepiandrosterone sulfate, an androgen produced almost entirely by the adrenal glands. In women, it helps determine whether acne, excess facial or body hair, scalp hair thinning, irregular periods, or virilization may have an adrenal contribution. Mild or moderate elevation can occur with PCOS, while a markedly high result may raise concern for an adrenal tumor or another adrenal steroid disorder. The test does not diagnose PCOS, and a normal level does not exclude androgen excess from the ovaries. DHEA-S changes substantially with age, peaking in early adulthood and declining over time, so an age-specific reference interval is essential. Supplements containing DHEA can raise the result, and some medications or illnesses can lower it. Clinicians interpret DHEA-S with testosterone, SHBG, androstenedione, 17-hydroxyprogesterone, symptoms, and the pace of change. Rapid virilization or a value several times above the upper limit requires more urgent evaluation than a stable, slight elevation.
- DHEA-S is mainly an adrenal androgen marker; ovarian production contributes very little.
- Mild elevation can occur in PCOS, but a very high value may prompt adrenal imaging.
- Age-specific ranges are essential because DHEA-S normally declines from early adulthood onward.
- DHEA supplements, some compounded products, and anabolic agents can cause misleadingly high results.
- A normal DHEA-S does not rule out PCOS, high testosterone, or an ovarian androgen source.
- Rapid voice change, clitoral enlargement, major muscle change, or sudden severe hirsutism needs prompt care.
Table of Contents
- What DHEA-S Measures
- Why Women Are Tested
- Preparation and Timing
- Normal, High, and Low Results
- PCOS and Adrenal Causes
- Follow-Up Tests and Imaging
- Treatment and Monitoring
What DHEA-S Measures
DHEA-S is the sulfated form of dehydroepiandrosterone, or DHEA. The adrenal cortex produces DHEA and converts much of it to DHEA-S by adding a sulfate group. That modification makes DHEA-S more stable in the bloodstream and gives it a longer half-life than DHEA. Its concentration changes less dramatically over the day, which makes it a practical marker of adrenal androgen production.
DHEA-S is a weak androgen by itself, but tissues can convert it into DHEA, androstenedione, testosterone, and estrogens. The effect of a given blood level depends on those local conversions, SHBG, receptor sensitivity, and the concentration of stronger androgens. This is why a woman can have significant hirsutism with a normal DHEA-S, or an elevated DHEA-S with only mild symptoms.
The ovaries contribute little directly to DHEA-S. A high level therefore points toward increased adrenal production or an external source such as a supplement. It does not automatically prove adrenal disease. The adrenal glands can produce more DHEA-S as part of PCOS-related androgen excess without a structural adrenal abnormality.
DHEA-S is measured in serum and commonly reported in mcg/dL, µmol/L, or sometimes mg/L. Unit conversion is necessary before comparing results. Reference intervals are usually separated by age and sex because levels are high in young adulthood and fall steadily with aging.
The test differs from a DHEA blood test. DHEA has more short-term fluctuation and is less commonly used in routine hyperandrogenism evaluation. DHEA-S generally provides a more stable view of adrenal androgen output.
The assay method matters. Immunoassays are widely used, while LC-MS/MS may offer greater specificity. When the number is extremely high, does not match symptoms, or will trigger imaging, confirmation with a reliable method can prevent an incorrect diagnosis.
Why Women Are Tested
A clinician may order DHEA-S when a woman has signs of androgen excess or when a testosterone result suggests a need to identify the source. Common reasons include:
- Coarse facial or body hair in an androgen-sensitive pattern
- Persistent acne with menstrual irregularity
- Scalp hair thinning combined with other androgen symptoms
- Irregular periods, absent periods, or difficulty ovulating
- High total or free testosterone
- Rapid virilization, including voice deepening or clitoral enlargement
- Suspected PCOS, nonclassic congenital adrenal hyperplasia, or Cushing syndrome
- An adrenal mass found on imaging
- Early pubic or underarm hair development in a child or adolescent
- Monitoring selected adrenal conditions under specialist care
DHEA-S is especially useful when clinicians are deciding whether androgen excess is likely to be ovarian, adrenal, or mixed. High testosterone with normal DHEA-S can fit an ovarian source, while very high DHEA-S raises concern for an adrenal source. Many women with PCOS have both ovarian and adrenal contributions, so the patterns overlap.
The test is not a general measure of adrenal “strength,” stress, fatigue, or wellness. Low energy, poor sleep, and difficulty coping with stress do not establish a DHEA-S disorder. The term “adrenal fatigue” does not describe a recognized adrenal failure syndrome, and DHEA-S alone cannot diagnose adrenal insufficiency.
DHEA-S also does not measure cortisol. Suspected cortisol excess or deficiency requires specific testing such as late-night salivary cortisol, 24-hour urine free cortisol, dexamethasone suppression, morning cortisol, or ACTH stimulation, depending on the clinical question.
In women with hirsutism, DHEA-S is usually interpreted within a hirsutism hormone test panel rather than alone. Total testosterone or calculated free testosterone is generally the most sensitive first-line biochemical measure of androgen excess, while DHEA-S adds information about adrenal contribution.
Preparation and Timing
DHEA-S is relatively stable across the day compared with DHEA or cortisol, so strict morning timing is less critical. Many clinicians still collect it in the morning because other androgens and 17-hydroxyprogesterone on the same order are best measured then.
Fasting is not usually required for DHEA-S alone. It may be required when fasting glucose, insulin, or lipids are being tested at the same visit.
Menstrual-cycle variation is modest, but early-follicular testing may improve consistency when DHEA-S is measured with testosterone, androstenedione, and 17-OHP. If cycles are absent or very irregular, the sample can be drawn on any day and interpreted with the clinical context.
The most important preparation step is reviewing products that contain hormones or hormone precursors. Tell the clinician about:
- DHEA or “7-keto DHEA” supplements
- Testosterone creams, pellets, gels, or injections
- Compounded hormone products
- Bodybuilding or performance supplements
- “Adrenal support” products
- Hormonal contraception or menopausal hormone therapy
- Glucocorticoids such as prednisone or dexamethasone
- Fertility medication and recent ovarian stimulation
DHEA supplements can raise DHEA-S substantially. Product labels may not always reflect the actual dose, and some supplements contain undeclared steroid ingredients. Do not assume a high result reflects internal disease until exposure has been reviewed.
Glucocorticoids suppress ACTH and can lower adrenal androgen production. Estrogen-containing contraception can change SHBG and ovarian androgens, although its effect on DHEA-S is less direct. Hormonal therapy can still alter the overall pattern enough to affect interpretation.
Acute illness and major physiologic stress can influence adrenal steroids. A surprising result obtained during severe illness may need confirmation after recovery. Pregnancy also changes adrenal and placental steroid metabolism, so nonpregnant ranges should not be applied.
When repeat testing is needed, use the same laboratory and similar collection conditions. A change between different methods may reflect assay calibration rather than a true biological shift.
Normal, High, and Low Results
DHEA-S reference ranges vary more by age than many other androgen tests. A result normal for a 25-year-old may be unexpectedly high for a 65-year-old. Laboratories may separate intervals into decade-based groups or broader age bands.
Typical adult female ranges can extend from roughly 35 to more than 400 mcg/dL depending on age. Those numbers are only illustrative. The printed age-specific range from the performing laboratory should be used first.
| Pattern | Possible meaning | Typical next step |
|---|---|---|
| Within age-specific range | No clear adrenal androgen excess | Evaluate testosterone and other causes if symptoms continue |
| Mild elevation | PCOS, supplement exposure, assay variation, or mild adrenal overproduction | Review products and repeat if unexpected |
| Moderate persistent elevation | PCOS with adrenal contribution, NCCAH, or another adrenal disorder | Add 17-OHP, testosterone, and targeted endocrine testing |
| Marked elevation, often around or above 700 mcg/dL | Possible adrenal neoplasm, especially with rapid virilization | Prompt confirmation and adrenal imaging |
| Low result | Age-related decline, glucocorticoid effect, adrenal insufficiency, or pituitary suppression | Assess cortisol and ACTH only when symptoms support it |
The often-cited 700 mcg/dL threshold is not a universal rule. Some tumors produce lower levels, and some benign conditions or supplement exposures can produce high values. The degree above the age-specific upper limit, the assay, and the clinical pace are more informative than one cutoff.
A result two or three times the upper limit is more concerning than a value 10% above it. Rapid voice change, clitoral enlargement, increased muscle mass, or abrupt severe hirsutism increases concern even when DHEA-S is below a traditional tumor threshold.
Low DHEA-S is common with aging and usually does not require treatment. It can also occur with adrenal insufficiency, pituitary ACTH deficiency, chronic glucocorticoid use, severe illness, or removal of the adrenal glands. Because symptoms such as fatigue and low libido are nonspecific, low DHEA-S should not be used alone to diagnose adrenal or androgen deficiency.
DHEA-S can be falsely elevated through assay interference. Confirmation is especially useful when the result is extreme but testosterone, androstenedione, imaging, and symptoms do not fit.
Interpretation improves when the androgen pattern is considered as a whole:
- High DHEA-S with high testosterone can reflect mixed adrenal and ovarian androgen excess, severe PCOS, or an adrenal lesion that produces several steroids.
- High DHEA-S with normal testosterone may represent mild adrenal overproduction, supplement use, or a laboratory issue, especially when symptoms are absent.
- Normal DHEA-S with high testosterone makes a dominant ovarian source more likely but does not prove it.
- Low SHBG with modest total testosterone can still produce high free testosterone and significant symptoms even when DHEA-S is normal.
- High 17-OHP with androgen excess shifts attention toward NCCAH rather than routine PCOS.
Age can change the level of concern. A DHEA-S of 350 mcg/dL may fall within range for a young adult but be distinctly abnormal after menopause. Always use the age-specific upper limit rather than a single internet cutoff.
PCOS and Adrenal Causes
PCOS
PCOS is the most common explanation for gradual androgen symptoms in reproductive-age women. About a subset of women with PCOS have elevated DHEA-S, reflecting increased adrenal androgen production. The level may be mildly or moderately high rather than tumor-range.
A high DHEA-S does not establish PCOS. Diagnosis depends on ovulatory dysfunction, androgen excess, and qualifying ovarian morphology or an accepted equivalent, after excluding other causes. Thyroid disease, high prolactin, nonclassic congenital adrenal hyperplasia, and severe androgen disorders should be considered.
A PCOS blood test panel also addresses metabolic risk. DHEA-S says little about glucose tolerance, lipids, blood pressure, sleep apnea, or endometrial exposure.
Nonclassic congenital adrenal hyperplasia
NCCAH, most often caused by partial 21-hydroxylase deficiency, can produce hirsutism, acne, irregular cycles, and infertility. DHEA-S may be high, normal, or only mildly changed. The preferred screening marker is early-morning 17-hydroxyprogesterone, followed by ACTH stimulation when indicated.
A normal DHEA-S therefore does not exclude NCCAH. The steroid pathway pattern and 17-OHP response are more useful.
Adrenal tumors
Androgen-secreting adrenal tumors are rare. Adrenocortical carcinoma may produce DHEA-S along with testosterone, androstenedione, cortisol, or steroid precursors. Symptoms often develop quickly. Possible associated signs include easy bruising, purple abdominal stretch marks, muscle weakness, high blood pressure, new diabetes, abdominal fullness, or pain.
Benign adrenal adenomas rarely produce substantial isolated androgen excess. An adrenal mass and a high DHEA-S require endocrine assessment to determine whether the lesion is functional and whether other hormones are being secreted.
Cushing syndrome
Cushing syndrome can cause acne, hirsutism, irregular periods, and elevated androgens, but DHEA-S varies with the source. ACTH-dependent Cushing disease may raise adrenal androgens, while an autonomous cortisol-producing adrenal tumor can suppress ACTH and lower DHEA-S. A normal result does not exclude cortisol excess.
Adrenal insufficiency and pituitary disease
Low DHEA-S can support an adrenal or central insufficiency pattern but lacks enough specificity to diagnose it. Morning cortisol, ACTH, electrolytes, symptoms, and stimulation testing determine the diagnosis. DHEA-S is sometimes helpful when cortisol results are borderline, especially in younger adults, but it remains an adjunct.
Follow-Up Tests and Imaging
The next step depends on severity and whether the result fits the symptoms.
- Confirm age-specific interpretation. Compare the value with the correct age and sex interval.
- Review supplements and external exposure. Stop or adjust only under clinician guidance, then repeat when appropriate.
- Measure related androgens. Total testosterone, free or calculated free testosterone, SHBG, and androstenedione help define the pattern.
- Screen for NCCAH. Early-morning 17-OHP is appropriate when hyperandrogenism is present.
- Evaluate menstrual causes. Pregnancy testing, TSH, prolactin, FSH, LH, and estradiol may be needed.
- Assess cortisol when clinical signs support it. Use a validated Cushing or adrenal-insufficiency test rather than random cortisol alone.
Adrenal CT or MRI is considered when DHEA-S is markedly elevated, symptoms progress rapidly, several adrenal steroids are abnormal, or an adrenal mass is already suspected. Imaging is not usually needed for a mild isolated elevation in a woman with long-standing PCOS features.
Pelvic imaging may still be necessary because ovarian tumors can raise testosterone while DHEA-S remains normal. Severe androgen excess should not be labeled “adrenal” or “ovarian” from one marker without considering the entire profile.
A practical distinction is urgency. A stable DHEA-S 15% above the upper limit with years of mild hirsutism can usually be repeated and evaluated methodically. A value several times above the limit with voice change over three months requires prompt endocrine review and imaging.
Useful questions after an abnormal result include whether the value was compared with the correct age range, whether DHEA or testosterone exposure is possible, whether LC-MS/MS confirmation is available, and which companion androgen is most abnormal. Asking whether the result changes the need for imaging helps distinguish a meaningful repeat test from low-value surveillance.
Postmenopausal women deserve special attention when symptoms are new. Mild facial hair can increase as estrogen and SHBG fall, but sudden acne, severe hirsutism, voice deepening, or clitoral enlargement is not a routine part of menopause. DHEA-S helps identify an adrenal contribution, while testosterone and pelvic imaging evaluate ovarian causes such as hyperthecosis or a tumor.
After an adrenal mass is found, clinicians may test cortisol, aldosterone and renin, metanephrines, and other steroids depending on blood pressure, potassium, imaging features, and symptoms. Biopsy is generally not the first step for a potentially functional adrenal lesion.
Treatment and Monitoring
Treatment targets the cause and the patient’s priorities rather than DHEA-S alone.
For PCOS, management may include combined hormonal contraception, antiandrogen treatment, acne therapy, hair-removal methods, metabolic risk reduction, and ovulation induction when pregnancy is desired. Spironolactone and other antiandrogens require pregnancy prevention because of fetal risk.
NCCAH treatment is individualized. Some women need only symptom-directed therapy. Glucocorticoids may be considered for selected fertility or severe hyperandrogenism situations, but overtreatment can cause weight gain, bone loss, glucose problems, high blood pressure, and adrenal suppression.
An androgen-secreting adrenal tumor usually requires specialist surgical evaluation. DHEA-S may be followed after treatment to help confirm biochemical response, but imaging and clinical recovery remain important.
DHEA supplementation is not a routine treatment for a low laboratory value in women. Research on sexual function, mood, aging, and fertility has produced mixed results, and supplements can cause acne, hirsutism, scalp hair loss, oily skin, and hormone-sensitive effects. They can also complicate evaluation by raising multiple androgens.
Routine repeat DHEA-S testing is unnecessary for stable PCOS when the diagnosis and treatment plan are clear. Monitoring is more useful when the original result was markedly abnormal, a supplement has been discontinued, an adrenal condition is being treated, or symptoms change rapidly.
When a supplement is the likely cause, the repeat interval should allow enough time for exposure and downstream hormone effects to clear. The clinician may also repeat testosterone and androstenedione because DHEA is converted into both. A single lower DHEA-S after stopping a product supports the explanation, but persistent elevation deserves the same structured evaluation as an untreated abnormal result.
Do not use over-the-counter DHEA to “balance” a low value without medical advice. The supplement can push women into an androgen-excess range and may be unsafe in pregnancy or hormone-sensitive conditions.
Existing hirsutism may persist after hormones improve because terminal hairs have already developed. Medical therapy mainly slows new growth and reduces thickness over months. Laser or electrolysis may be needed for visible hair already present.
A DHEA-S result is most valuable as a directional clue: it tells the clinician how much adrenal androgen production may be contributing. It becomes diagnostic only when combined with other hormones, symptoms, age, medications, and imaging when appropriate.
The number should also be tied to a clinical endpoint. In PCOS, the more important follow-up may be cycle regularity, endometrial protection, glucose tolerance, blood pressure, or unwanted hair rather than normalization of DHEA-S. In an adrenal tumor, by contrast, a falling level after treatment can be a useful marker of response. The purpose of monitoring changes with the diagnosis.
Using age and trend without overreacting
DHEA-S is highest in early adulthood and generally declines with age, so a result should be compared with an age-appropriate interval. A value that is only slightly above the range in a woman without rapid symptom progression is commonly confirmed before imaging. Repeating the test after stopping nonessential DHEA-containing products, using the same laboratory when possible, and checking the companion androgen pattern can separate a persistent adrenal signal from a temporary or analytical finding.
Trend is most helpful when the clinical situation also changes. A steadily rising DHEA-S together with rapidly increasing hirsutism or virilization is more concerning than two mildly different values near the upper limit. Conversely, a stable mild elevation over years with a typical PCOS pattern rarely justifies serial adrenal scans. Imaging should answer a focused question raised by the magnitude, repeat result, symptoms, and other hormones—not serve as an automatic response to one flagged number.
References
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women 2025 (Guideline)
- Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines 2025 (Systematic Review)
- Approach to androgen excess in women: Clinical and biochemical insights 2022 (Review)
- Practical Approach to Hyperandrogenism in Women 2021 (Review)
- International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023 – Summary 2023 (Guideline)
Disclaimer
This article provides general education and cannot diagnose PCOS, adrenal disease, or an androgen-secreting tumor. DHEA-S ranges vary substantially by age, assay, medication use, and laboratory. Seek prompt medical evaluation for rapidly developing virilization, severe weakness, fainting, or a result several times above the age-specific upper limit.
